SCHEMBL2893202

SCHEMBL2893202

Cn1c(-c2cc(F)cc(F)c2)n[nH]c1=S

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.59
LMNA P02545 1/20 0.59
APOBEC3G Q9HC16 7/20 0.54
ALDH1A1 P00352 6/20 0.54
KDM4E B2RXH2 8/20 0.53
HPGD P15428 5/20 0.53
TDP1 Q9NUW8 2/20 0.53
POLB P06746 1/20 0.53
ALOX15 P16050 1/20 0.53
TSHR P16473 3/20 0.49
MAPT P10636 1/20 0.49
GFER P55789 1/20 0.49
PKM P14618 1/20 0.47
GAA P10253 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RXFP1 Q9HBX9 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544445 0.82 HSD17B10 (0.74) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL13983884 0.79 BCHE (0.57) HSD17B10APOBEC3GALDH1A1KDM4EHPGD
SCHEMBL31119462 0.77 ALDH1A1 (0.60) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL1544475 0.73 HSD17B10 (0.71) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL9179007 0.72 PTGS2 (0.58) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL24818613 0.71 KDM4E (0.59) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL2316369 0.71 ALDH1A1 (0.74) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL3105626 0.70 HSD17B10 (0.53) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL9222389 0.70 HSD17B10 (0.61) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E
SCHEMBL3108445 0.69 HSD17B10 (0.55) HSD17B10LMNAAPOBEC3GALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1716125-B1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2013-06-19 EP disclosed
US-7691892-B2 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2010-04-06 US disclosed
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-23 US disclosed
EP-1716125-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS AstraZeneca AB (SE) 2006-11-02 EP disclosed
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-05 US disclosed
WO-2005080356-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 HSD17B10 4045/4885LMNA 4488/4885APOBEC3G 4774/4885
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 HSD17B10 4154/4885LMNA 4515/4885APOBEC3G 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.